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Background – This study sought to identify and describe the clinical and behavioural 
components (e.g. the what, how, when, where and by whom) of ‘selective decontamination of 
the digestive tract’ (SDD) as routinely implemented in the care of critically ill patients. 
Methods – Multi-methods study, consisting of semi-structured observations of SDD delivery, 
interviews with clinicians and documentary analysis, conducted in two ICUs in the UK that 
routinely deliver SDD.  Data were analysed within-site to describe clinical and behavioural 
SDD components and synthesised across-sites to describe SDD in context. 
Results – SDD delivery involved multiple behaviours extending beyond administration of its 
clinical components.  Not all behaviours were specified in relevant clinical documentation.  
Overall, SDD implementation and delivery included:  adoption (i.e. whether to implement 
SDD), operationalisation (i.e. implementing SDD into practice), provision (i.e. delivery of 
SDD) and surveillance (i.e. monitoring the ecological effects).  Implementation involved 
organisational, team and individual-level behaviours.  Delivery was perceived as easy by 
individual staff, but displayed features of complexity (including multiple interrelated 
behaviours, staff and contexts). 
Conclusions – This study is the first to formally outline the full spectrum of clinical and 
behavioural aspects of SDD.  It identified points in the delivery process where complex 
behaviours occur and outlined how SDD can be interpreted and applied variably in practice.  
This comprehensive specification allows greater understanding of how this intervention could 
be implemented in units not currently using it, or replicated in research studies.  It also 
identified strategies required to adopt SDD and to standardise its implementation. 
Key words:  behaviour, infection control, critical care  
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Introduction 
Healthcare interventions are typically complex 
1
 and involve two broad interacting 
categories of components:  1. clinical components, i.e., the clinical materials or equipment of 
the intervention and related features and 2. associated behavioural aspects i.e., the actual 
behaviours required to deliver the intervention in practice.  Healthcare interventions are often 
specified clinically without explicitly addressing associated behavioural aspects required for 
successful delivery 
2, 3
.  Thus, interventions may be implemented differently across sites, 
potentially leading to variable effectiveness and resultant consequences for patient outcomes.  
The need to fully describe healthcare interventions has been widely recognised, together with 
the need to report interventions in such a way as they could be directly replicated by others 
4
. 
Selective decontamination of the digestive tract (SDD) is an intervention that has been 
shown to reduce hospital acquired infection rates and mortality in critically ill patients 
5-7
.  
SDD involves the application of antibiotics and antifungals to the mouth, throat and stomach 
combined with a short course of intravenous antibiotics 
8
.  Despite considerable evidence 
supporting the benefit of SDD 
5-7
, adoption internationally is low 
9, 10
.  Amongst proposed 
reasons for this lack of adoption are controversies surrounding prophylactic use of antibiotics 
and associated risk of antibiotic resistance 
11, 12
 and purported difficulty of SDD 
implementation and delivery 
13
. 
Considerable variation exists in the clinical components of SDD evaluated in trials 
and used in clinical practice.  A recent systematic Cochrane review noted that trials used 
different SDD protocols and investigators use different definitions for SDD 
6
.  In addition, 
behaviours related to the delivery of SDD have not been systematically described in the 
literature.  As such, a standardised and fully specified protocol outlining both clinical 
components and associated behavioural aspects of SDD implementation and delivery in 
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practice does not exist but could be very beneficial in both widespread clinical adoption and 
future effectiveness or implementation trials. 
This study sought to describe the clinical components and associated behaviours 
related to SDD implementation and delivery in clinical practice. 
Methods 
Study Design 
An in-depth multi-methods study design 
14
 was used in two UK intensive care units 
(ICUs) where SDD was routinely administered - with the ‘site’ (unit of analysis) consisting of 
an ICU.  Data were collected from three sources: direct observation of SDD delivery at the 
bedside; face-to-face semi-structured interviews with clinicians responsible for implementing 
and/or delivering SDD; and systematic assessment of written documentation (e.g., SDD 
protocols, training documents) (Figure 1). 
___________________________Figure 1___________________________ 
Sampling and recruitment 
All UK ICUs delivering SDD, identified from a recent national SDD survey 
9
, or 
known by the study investigators to deliver SDD were deemed eligible for inclusion (15 
ICUs).  Two ICUs were purposively selected to represent recent and more remote lengths of 
time since SDD adoption and different geographical locations (i.e. geographically dispersed 
ICUs to ensure different organisational profiles).  For interviews we recruited a purposive 
sample of clinicians based on profession (i.e. intensivists, medical microbiologists, specialist 
clinical pharmacists and ICU nurses) and involvement in the implementation and/or delivery 
of SDD.  This study was classified as service evaluation by the Research Ethics Committee 
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(10/MRE00/32) and was deemed by them not to require ethical approval.  All participants 
observed and interviewed were aware of the study purpose and provided verbal consent prior 
to data collection. 
Materials 
Observations were conducted using an investigator-designed form to record all 
behaviours relating to ‘real time’ delivery of SDD.  Additionally, the context (i.e. the physical 
environment where behaviours were performed), timing of procedures and physical presence 
of healthcare providers at time of delivery were recorded. 
Semi-structured face-to-face clinician interviews were conducted in the study 
hospitals using a topic guide with pre-specified prompts to ensure consistent coverage of key 
issues including behaviours relating to SDD implementation and SDD delivery as well as 
barriers and facilitators of described behaviours. 
Lastly, written documentation relating to SDD implementation and delivery (e.g. 
SDD protocols, training documents) were provided by the participating ICUs for systematic 
analysis. 
Procedure 
Data collection commenced with observation of SDD delivery performed by various ICU 
nurses to different patients at the bedside.  Semi-structured interviews were conducted in 
parallel with observations.  Observed nurses were included in the interview sample to gain an 
in-depth understanding of observed behaviours.  With participants’ permission, interviews 
were audio-recorded, transcribed verbatim and anonymised.  Written documentation from 
each ICU was examined following completion of all observations and interviews to minimise 
researcher bias during these stages. 
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Analysis 
Data from the three sources were analysed within-site to describe the clinical 
components and behavioural aspects of delivery and synthesised across-site to identify 
emergent themes describing SDD implementation and delivery in context.  The analytical 
process was guided by the study aims that included identification of the clinical components 
and behavioural aspects of SDD and exploration of the implementation and delivery of SDD 
in practice. 
The three data sources were analysed separately and in reverse order to data collection 
(Figure 1).  First, we systematically examined written documentation and extracted the 
clinical components and the associated behavioural aspects of SDD delivery.  Clinical 
components were defined as the pharmaceutical regimens forming part of SDD including 
drug, dose, route, frequency and duration.  Associated behavioural aspects were defined as 
any actions or behaviours that were/would be directly observable.  We recorded the 
behaviours involved in delivering the clinical components and those not related specifically 
to drug administration.  Second, we performed content analysis 
15
 of interview transcripts to 
identify additional behaviours involved in SDD delivery (i.e., those not specified in the 
documents).  Third, direct observations provided contextual ‘real time’ data 14 and identified 
new and corroborative evidence on SDD clinical components and associated behavioural 
aspects, (i.e. data triangulation from multiple sources) 
14
. 
To identify features of SDD implementation and delivery across units, a thematic 
analysis of the interview data was conducted using a framework approach 
16
. This involved 
coding the data for emergent themes relating to the behaviours and clinician groups involved.  
A single researcher (SUD) coded the data, a second researcher (ED) independently coded 
randomly selected portions of the dataset to identify clinical components and associated 
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behavioural aspects and three researchers (MP, JJF, LR) provided critical comments on 
analyses drafts. 
Results 
Site 1 implemented SDD 3.5 years prior to this study in response to increased hospital 
acquired infection rates and was the most recent adopter of SDD in the UK.  Collected data 
comprised 4 observations; 8 interviews (intensivists [n=3], nurses [n=3], microbiologists 
[n=1], pharmacists [n=1]) and 3 SDD documents (protocol, prescription chart, training 
slides).  Site 2 implemented SDD as part of an effectiveness trial 26 years prior to this study.  
Collected data comprised 3 observations; 8 interviews (intensivists [n= 3], nurses [n= 3], and 
pharmacists [n= 2]), and 1 document [protocol]). 
SDD Clinical Components and Associated Behavioural Aspects 
Protocols documenting the specific clinical behaviours required for drug preparation 
and administration in the two ICUs are detailed in Table 1, demonstrating the degree of 
clinical complexity and also the variation encountered in clinical components of SDD.  
Documentation listed 9 different medications and a total of 13 different preparations as part 
of SDD in the two sites (Table 1).  Several behaviours directly relevant for drug 
administration were identified in examined documentation. 
___________________________Table 1___________________________ 
Aside from clinical components and associated behavioural aspects directly relevant 
to SDD delivery, documents from both sites revealed several additional delivery behaviours 
performed by multiple clinicians in various clinical and environmental contexts (Table 2).  To 
complement understanding of associated behavioural aspects that are important in SDD 
delivery but not specifically mentioned in the examined documentation, Table 3 outlines 
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additional delivery behaviours identified through interviews and observations. Behaviours 
outlined in Table 2 and 3 were performed by various clinician groups (e.g. nurses, physicians, 
pharmacists) in a variety of clinical and environmental contexts (e.g. bedside, ICU nursing 
stations, pharmacy). 
___________________________Tables 2 and 3___________________________ 
Participant interviews were provided most data relating to behavioural aspects; 49 
components were identified through interviews, 22 in documentation and 12 via observations.  
Each data source gave rise to unique behaviours not mentioned in other sources, confirming 
the added value of analysing multiple information sources (28, 7 and 4 unique behavioural 
aspects for interviews, documentation and observations, respectively).  Twenty-nine and 9 
behavioural aspects, respectively, were unique to the two sites.  Twenty-six behavioural 
aspects were common across ICUs, being identified in at least one data source for each site.  
SDD Implementation and Delivery  
 Based on our analysis, SDD implementation and delivery was conceptualised as a 
complex procedure consisting of four overlapping processes each involving specific 
behaviours: adoption, operationalisation, provision and surveillance. Adoption concerned the 
decision to introduce SDD; operationalisation referred to the processes required to introduce 
SDD in to clinical practice. SDD provision included actions involved in delivery of the 
clinical components. Surveillance, mentioned in both sites, provided the foundation for 
adoption, operationalisation and provision by checking that SDD was effective in preventing 
infection.  
Adoption & Operationalisation 
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For adoption, we identified that actions often occurred at the organisational and team level 
involving organisational and group processes as well as individual actions. As the 
implementation process moved from adoption to operationalisation, more behaviours 
emerged that were performed by individual staff (Tables 2 and 3). Although 
operationalisation was complete following SDD introduction, elements of operationalisation 
continued due to clinician staff turnover (e.g., although SDD was a standard procedure within 
the ICUs, the low national baseline adoption meant that additional training for clinicians new 
to these ICUs and SDD delivery was required).  
Provision of SDD 
Three themes emerged from the interviews on SDD provision: complexity/difficulty, 
protocol adaptation in practice and facilitators and barriers.  
Complexity / difficulty 
Reflecting the theme of complexity one intensivist and several nurses reported that 
SDD provision represented additional and time consuming work leading to unpopularity with 
staff.  When examining the sequencing and flow of actions, we identified some evidence of 
complexity such as multiple clinicians being involved in managing various behaviours within 
multiple clinical and environmental contexts using a range of materials delivered in specific 
sequences in a continuing flow of action (see Box 1 for quotations).  However, most nurses 
and doctors refuted the idea that SDD was complex and time consuming stating that SDD 
provision was performed effortlessly (see Box 1 for quotations).  Low complexity / difficulty 
of SDD was supported by observational data that indicated administration of clinical 
components took no longer than 5 minutes, and often less, and was performed in a swift 
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sequence of actions.  It is important to note, however, that these were highly practised actions 
and may require considerable skill development to achieve this high level of expertise. 
____________________________Box 1____________________________ 
Protocol adaptation in practice 
Protocol adaptation in SDD delivery was noted in observational and interview data.  
Preparation of antibiotics/antifungals varied suggesting some deviation from recommended 
practice.  A further adaptation was evident in the provision of SDD oral components such as 
different ways of applying oral drug components and timing with other nursing interventions 
such as oral hygiene.  Authorisation of SDD involved multiple staff and deviation from 
recommended practice was noted.  Although documentation indicated patients should be 
routinely commenced on SDD, this was not always the case, due to more pressing clinical 
concerns.  As a result, multiple layers of control to ensure protocol adherence were described 
(see text box 2 for quotations). 
____________________________Box 2____________________________ 
 
Facilitators and barriers 
Various facilitators and barriers to SDD delivery were evident across both sites (Box 
3).  One facilitating factor frequently reported was ‘dovetailing’ of SDD with other 
established and routine procedures.  Thus, intensivists might include SDD delivery 
behaviours as part of the admission process. Nurses might include SDD as part of oral 
hygiene or other activities, and microbiologist and pharmacists dovetailed SDD actions 
within ward rounds.  Dovetailing was evident in multiple interviews and in documentary data 
12 
 
on SDD provision for oral hygiene. Although barriers were commonly reported during 
interviews in response to specific prompts, these were often referred to as minor 
inconveniences, rather than significant obstacles to SDD delivery (see text box 3 for 
quotations). 
____________________________Box 3____________________________ 
Infection Surveillance 
 Surveillance was specified in documentation outlining the SDD protocol in one of the 
sites, but not in the other, where it was part of the wider regimen to combat hospital acquired 
infections.  Despite these differences, surveillance was integral to the provision of SDD, and 
included the performance of multiple behaviours of various clinicians in several clinical and 
environmental contexts. 
Discussion 
In line with frameworks for intervention development 
1
 and description,
4
 this study is 
the first to formally seek to describe the full clinical components and associated behavioural 
aspects of SDD and to describe how they impact on SDD implementation and delivery in 
practice.  There are several advantages of describing an intervention behaviourally alongside 
clinical descriptions.  First, it demonstrates procedural complexity and the situations in which 
complexity may be experienced. This information has direct relevance to clinicians and 
hospital decision-makers considering implementation of particular healthcare interventions. It 
also can inform the scale and content of implementation strategies to facilitate diffusion and 
adoption within specific contexts 
17
.  Second, behavioural specification identifies potential 
areas where behavioural variation in practice may occur and thus allows prior specification of 
acceptable limits of protocol adaptation. Thirdly it can identify whether formal training for, 
13 
 
and monitoring of, adherence to an expected standard of intervention delivery will be 
required.  Fourthly, it may identify training needs to facilitate adherence to an expected 
standard. Finally, behaviour specification facilitates precision in protocols and training 
materials by describing what should be done, by whom, when and where. 
 We found variation in the clinical components of SDD, in terms of the drug regimen, 
mode of drug delivery and specification of components between the two study sites.  This 
may be appropriate and could be the result of local tailoring to make the intervention simple 
and feasible to deliver.  Various behaviours directly related to drug provision as well as 
relevant to the SDD intervention (e.g. authorisation of SDD delivery) were performed by 
multiple clinicians in differing contexts.  Overall, SDD implementation and delivery 
comprised the interrelated phases of SDD adoption, operationalisation, provision and 
surveillance. 
Additional behaviours to those specified in documentation were identified.  These 
behaviours are essential for SDD delivery.  SDD involved a range of healthcare professionals 
performing various behaviours in differing contexts.  These findings emerged from the 
interview and observational evidence but were not always clearly specified in the 
documentation.  Ensuring that these additional behaviours are specified in protocols, 
guidelines and the academic literature should lead to improvements in implementation, 
delivery and reproducibility of SDD 
2, 3
. 
Various behaviours were identified in order to implement SDD, many at the 
organisational and team level and others at the individual level.  Several features of 
operationalisation identified an on-going process (e.g. nurse training for SDD provision) due 
to staff turnover.  SDD might be perceived as a simple and easy intervention from the 
individual behavioural perspective that becomes increasingly complex when focusing on the 
14 
 
flow of actions required at an organisational level for its delivery in practice.  Consequently, 
some of the barriers and facilitators to SDD provision tended to centre on the environmental 
context and resource issues, rather than specific attitudinal (e.g. beliefs about SDD 
effectiveness) or skills barriers.  Clinicians in ICUs not delivering SDD might include 
different views potentially preventing SDD rollout, requiring further research in this area 
18
. 
Strengths and limitations 
A limitation of this exploratory study is the potential lack of generalisability due to 
the use of only two sites. Additional clinical and behavioural components as well as 
alternative methods of SDD implementation and delivery may be evident if investigating 
SDD practice in a larger number of ICUs.  However, the study was exploratory in nature with 
the goal of providing information-rich case studies that facilitate in-depth understanding of 
SDD in practice rather than a comprehensive picture of SDD across all UK ICUs.  We 
recruited only one microbiologist, limiting the perspective from this profession. Lastly, 
clinicians in ICUs not delivering SDD may have different views about barriers to SDD 
implementation. This was investigated systematically in a larger programme of work 
19
, but 
was beyond the remit of the study reported here.  
Conclusion 
This study is the first to develop a formal description of the full clinical and 
behavioural components of SDD and to describe how they impact on SDD implementation 
and delivery in practice.  We identified a wide range of behaviours involved in delivering 
SDD, several of which were not included in local SDD protocols.  Significant protocol 
adaptations resulting from these behaviours were observed across sites – supporting the need 
for routine behavioural specification in SDD delivery protocols.  Such routine specification 
15 
 
would greatly facilitate the subsequent detection of acceptable variations and those that might 
lead to significant differences in patient outcomes. 
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Table 1:  Protocolised or documented clinical components and behaviours involved in delivery of SDD medications in the two ICUs. 
Drugs Dose Route Frequency Specific 
Behaviours 
(what) 
Directions 
(how) 
Frequency/duration 
(when) 
 
Site 1 
     
Cefuroxime  1.5g (6 
doses) 
over 3-5 
minutes  
intravenous  8 hourly  Prepare drug  
Administer drug  
Dilute 1.5g in 15ml of water for 
injection  
Administer intravenously over 3-5 
minutes  
Immediately after obtaining 
all admission surveillance 
and diagnostic 
microbiological samples and 
then at 8 hourly intervals  
Ciprofloxacin 
(if allergic to 
Cefuroxime)  
400mg (4 
doses) 
over 60 
minutes  
Intravenous  12 hourly  Prepare drug  
Administer drug  
Administer 400mg intravenously 
over 60 minutes  
Immediately after obtaining 
all admission surveillance 
and diagnostic 
microbiological samples and 
then at 12 hourly intervals  
Nystatin  100,000 
units/ml  
Oral & 
gastric tube  
8 hourly  Prepare drug  
Administer drug  
Administer 5ml topical to mouth and 
5ml via gastric tube. Use a new 30ml 
bottle every 24 hours. If gastric tube 
on free drainage, flush tube with 
20ml sterile water and clamp for 30 
minutes after administration of 
antibiotics/antifungals  
3x daily after oral hygiene 
regimen  
Vancomycin 500mg Oral &  
gastric tube 
6 hourly* Prepare drug 
Administer drug 
Reconstitute a 500mg vial with 10ml 
water for injections and administer 
250mg into the mouth and 250mg 
via gastric tube. 
4x daily after oral hygiene 
regimen 
Colistin 
sulphate  
250,000 
units/ml  
Oral & 
gastric tube  
6 hourly*  Prepare drug  
Administer drug  
Reconstitute a vial (licensed for 
injection) of 1 million units with 
4x daily after oral hygiene 
regimen  
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sodium chloride (NaCl) 0.9%. Dilute 
the reconstituted vial to a total of 
40ml with NaCl 0.9%. This solution 
may be kept at the bed space for 24 
hours. Administer 5ml (125,000 
units) of this solution into the mouth 
& 5ml via gastric tube.  
Tobramycin  80mg  Oral & 
gastric tube  
6 hourly*  Prepare drug  
Administer drug  
Dilute one ampoule of 80mg 
(licensed for injection) in 10ml 
NaCl0.9%. Give 5ml (40mg) into 
mouth and 5ml (40mg) by gastric 
tube  
4x daily after oral hygiene 
regimen  
Chlorhexidine 
gluconate  
4% liquid soap  
15ml  Topical  12 hourly  Administer body 
wash  
Use 15ml for body wash with water  2x daily  
Chlorhexidine 
gluconate  
0.2% 
mouthwash  
10ml  Topical  6 hourly*  Administer 
mouthwash  
Not to be swallowed. Apply with 
pink sponge stick to teeth, gums, 
tongue and lining of the mouth as 
part of thorough mouth care  
2x daily before each 
application of topical 
antibiotics  
 
 
Site 2 
     
Tobramycin, 
Colistimethate 
sodium (colistin), 
Amphotericin B, 
prepared by 
Pharmacy 
2% 
w/w of 
each 
constitu
ent 
Topical 6 hourly* Administer gel 
to oropharynx 
Apply gel to palate and buccal 
surfaces 
Within 4 hours of admission 
4x daily for duration of ITU 
admission 
Until discharge 
21 
 
Manufacturing 
Unit 
 
Tobramycin 
27mg/ml liquid † 
80mg NG tube 6 hourly* Administer 
solution 
/suspension  
Deliver solution/ suspension via 
nasogastric tube 
4x daily for duration of ITU 
admission 
 
Colistimethate 
sodium (colistin) 
50mg/ml liquid † 
100mg NG tube 6 hourly* Administer 
solution/suspens
ion  
Deliver solution/ suspension via 
nasogastric tube 
4x daily for duration of ITU 
admission 
 
Amphotericin B 
100mg/ml liquid 
† 
500mg NG tube  6 hourly* Administer 
solution/suspens
ion  
Deliver solution/ suspension via 
nasogastric tube 
4x daily for duration of ITU 
admission 
Note.  *Components typically administered at the same time, † Prepared separately by local Pharmacy Manufacturing Unit and drawn up by the 
nurse together into an oral syringe, prior to administration.  
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Table 2:  Documented behaviours for delivery of SDD not related specifically to drug administration 
Behaviour Professional Group Context Site 1 Site 2 
Clarifying SDD regimen (in ambiguous 
cases) 
Nurse, Intensivist, 
Pharmacist, Microbiologist 
ICU and bedside X X 
Authorise SDD delivery Intensivist, Pharmacist ICU (admission) and bedside X  
Prompt SDD authorisation Nurse ICU (admission) and bedside X  
Judging SDD delivery in unclear cases Intensivist ICU (admission) and bedside X  
Documenting SDD delivery Nurse ICU and bedside X  
Discarding of antibiotics (when out of date) Nurse Bedside X  
Storing reusable antibiotics Nurse ICU and bedside X  
Labelling leftover antibiotics/atifungals Nurse ICU and bedside X  
Check SDD is “continued and operating” Intensivist, Pharmacist ICU, bedside  X 
Note.  X = identified within site.  
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Table 3:  Additional behaviours of SDD delivery identified in interviews and observations but not in written protocols or procedures. 
Behavioural  Professional Group Context Site 1 Site 2 
Check patient eligibility for SDD  
 
Intensivist. Pharmacist ICU (admission) and bedside 
X
*
 X
*
 
Review and optimise SDD delivery 
Intensivist, Pharmacist, 
Microbiologist 
ICU, bedside 
X
*
 X
*
 
Attend ward rounds (at which SDD 
discussed)  
Intensivist, Pharmacist, 
Microbiologist 
ICU, bedside 
X
*
 X
*
 
Dispose of SDD waste Nurse Bedside 
X
*, † X† 
Order SDD drugs from pharmacy Nurse ICU 
X
*
 X
*
 
Reassure patient/patient visitors 
before/during SDD administration  
Nurse Bedside 
X† X
*, † 
Reposition patient for SDD 
administration  
Nurse Bedside 
X† X† 
Decision to discontinue SDD drugs  Intensivist, Pharmacist ICU and bedside 
X
*
 X
*
 
Print SDD documentation Ward clerk ICU 
X
*
  
Monitor for SDD drug reactions  Intensivist, Pharmacist Bedside X
*
  
Check stock and supply SDD drugs  Pharmacy Technician ICU X
*
  
Order SDD drugs from suppliers  Pharmacy Technician ICU 
X
*
  
Describe SDD during shift 
communication  
Nurse ICU and bedside 
X
*
  
Handling contraindications Nurse Bedside 
X†  
Collecting SDD drugs Nurse ICU and bedside X
*, †  
Preparation of antibiotics Pharmacist Production unit
2
 
 X
*
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Order raw materials Pharmacist Analytic lab
2
 
 X
*
 
Check of antibiotics quality Pharmacist Quality Assurance Department
2
 
 X
*
 
Liaise with pharmacy production unit Pharmacist ICU 
 X
*
 
Check naso/orogastric aspirate Nurse Bedside  X
*, 
† 
Note.  X = identified within site; * = identified through interview, † = identified through observation 
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Box 1:  Selected quotations on the level of difficulty / complexity of providing SDD. 
Quotes supporting difficulty of providing SDD:- 
“...there is extra work, four times a day,” Participant 1 
“...it’s relatively unpopular with most of the nursing staff […] because they see it as excess 
workload” Participant 10 
“...delivery […] can be difficult” Participant 5 
“It only takes five/ten minutes, although that is another five/ten minutes added on to the other 
five/ten minutes for everything else that you have to do”, Participant 7 
Quotes not supporting difficulty of providing SDD:- 
 “..it’s a part of your routine already so I don’t find it difficult, it’s just finding ways of how to 
do it, I mean it’s not too difficult” Participant 6 
“[SDD provision] is really straight forward” Participant 7 
“…very simple […], a fairly straight forward thing to do” Participant 3 
“… the main message to take across is that it’s, it works well.  It is very easy to do” 
Participant 13 
“I don’t find it difficult” Participant 14 
“It is not that hard.  It is really straight forward.”  Participant 15 
Quotes supporting complexity of providing SDD:-  
“[overall, SDD delivery] involves a large amount of co-operation between the 
microbiologists, the nursing staff and the medical staff to […] maintain an appropriate 
antibiotic policy; it also involves […] quite a lot of monitoring of what is involved with the 
patients […] so that we can manage the infections appropriately […] it involves applying 
some paste and some nasogastric SDD, but these are relatively minor parts of the whole.  It 
is a system of which that is part.” Participant 11 
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Box 2: Protocol adaptation in practice. 
“… although it says the dose is 500 mg I have been taught, in order to better manage my 
time, that I use [a] 1g bottle instead and instead of reconstituting it with 10ml I reconstitute it 
with 20ml” Participant 5 
“I have different ways […] because there are a lot of antibiotics” and he/she did not “know if 
it’s a good thing to mix all 4 antibiotics in one go and put them orally in one go also”, and 
that “...others might do it differently” Participant 14 
“...it sometimes slips off the main agenda of the patient’s day…”, Participant 8 
“I would ensure that all the relevant people get SDD”, Participant 17 
“I just make sure it is being put on”, Participant 11 
"if they haven’t prescribed it, I’ll ask them to prescribe”, Participant 14 
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Box 3:  Facilitators and barriers reported to influence SDD implementation and delivery. 
Facilitators 
 Policies and protocols, e.g. “We have an admission policy, so [patients] come in and we 
have a set of investigations and […] they’ll get SDD and […] that’s just part of the 
admission”, Participant 10 
 Patient state, e.g. “patient is deeply sedated, it’s easier,” Participant 1 
 Perceived effectiveness, e.g. “the fact that you have a very few incidents of pneumonia”, 
Participant 17 
 Colleague support, e.g. “if you’re working side by side with a nurse, that nurse will help 
you” Participant 5 
 Dovetailing, e.g. “you just tag it on with your aspirating stomachs,” Participant 15 
Barriers 
 Workload, e.g. “When it’s a really busy day then it gets a lot to do,” Participant 5 
 Patient state, e.g. “if they’re intubated and they’re just maybe biting” Participant 6 
 Side effects, e.g. “patients tend to get more diarrhoea when they are [on] SDD,” 
Participant 1 
 Staff changes, e.g. “losing a senior microbiologist was a stress, he was very supportive,” 
Participant 10 
 Cost, e.g. “The main challenges are the cost.  The drugs themselves cost a lot of money” 
Participant 10 
 Materials, e.g. “there’s been a few supply problems over the last couple of years. 
Sometimes […] there can be national shortages which can be a bit of a problem,” 
Participant 16 
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Figure 1:  Diagram of the study procedures 
Phase 2: 
Data analysis 
Phase 1:  
Data collection 
1.  Direct observation of ‘real time’ SDD 
delivery 
2. Interviews with clinicians involved in 
implementing &/or delivering SDD 
3. Written documentation  (e.g. SDD 
protocols) 
1. Documentary analysis to identify clinical 
and behavioural components of SDD  
2. Content analyse interviews to identify 
additional behaviours involved in SDD 
delivery 
3. Examine observational data to identify 
additional and corroborative evidence on 
clinical and behavioural components of SDD 
 
 
 
 
